Close Menu

At MIT's Tech Review, Emily Singer discusses new genetic tests launched by Decode this week. One looks for variations linked to various cardiovascular diseases and the other for variations associated with cancer risk and they are priced at $195 and $225. However, the clinical utility of tests that include multiple genetic risk factors hasn't yet been worked out. "We don't yet know how to combine such data in an accurate way," UNC-Chapel Hill's James Evans says.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

An analysis of blood donations suggests SARS-CoV-2 was present in the US weeks earlier than thought, according to NPR.

The Guardian reports that DeepMind Technologies' AlphaFold can predict how proteins fold.

CNBC reports that a US Centers for Disease Control and Prevention advisory panel is to vote on how to distribute COVID-19 vaccines.

In PNAS this week: targeting progesterone signaling in ovarian cancer, LINE-1 retrotransposition events in adenocarcinomas, and more.